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ABSTRACT

THE BIOACTIVE EFFECTS OF CHICORIC ACID AS
A FUNCTIONAL FOOD INGREDIENT
MAY 2019

YE PENG
B.S., NORTHWEST A & F UNIVERSITY, CHINA
M.S., UNIVERSITY OF GEORGIA, ATHENS, GEORGIA
Ph.D., UNIVERSITY OF MASSACHUSETTS, AMHERST, MA

Directed by: Professor Yeonhwa Park

Chicoric acid, a hydroxycinnamic acid, has been reported to possess a variety of
health benefits, including antivirus, anti-oxidation, anti-inflammation, obesity prevention
and neuroprotection effects. However, its role on aging and glucose homeostasis are
largely unknown. Therefore, the bioactive effects of chicoric acid on aging and glucose
homeostasis were determined using Caenorhabditis elegans (C. elegans) and C2C12
myotubes, respectively. Our study showed that chicoric acid (25 and 50 µM) significantly
extended the lifespan of C. elegans and increased median survival rates. The declines of
pumping rate and locomotive activity, two indicators of aging, were delayed by chicoric
acid. Chicoric acid also enhanced resistance to oxidative stress compared to the control.
These effects were in part via AAK-2 (a homolog of AMP-activated protein kinase) and
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SKN-1 (a homolog of nuclear factor erythroid 2-related factor 2). Furthermore, chicoric
acid significantly enhanced glucose uptake and the phosphorylation of protein kinase B
(Akt) as an indicator of insulin signaling pathway independent of insulin in C2C12
myotubes. These effects were dependent of the phosphorylation of 5'-AMP-activated
protein kinase α (AMPKα), via increasing the AMP/ATP ratio in C2C12 myotubes. Our
study may suggest the potential of chicoric acid to be used as an anti-aging and antidiabetic bioactive compound.
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CHAPTER 1
INTRODUCTION
Chicoric acid is a hydroxycinnamic acid presents in the roots of a large number of
plants (63 genera and species), including many plants grown in the Mediterranean area
(1), and many of these plants have been consumed traditionally as food ingredients and
alternative medicines for some time (2, 3). Because chicoric acid is found in especially
high amounts in chicory (Cichorium intybus), purple coneflower (Echinacea purpurea),
and basil, the acid is often used as a marker for the quality check of herbal products from
these plants (4). More recently, an increasing number of publications have reported the
beneficial effects of chicoric acid in cell culture and animal studies. However, its role on
aging and glucose homeostasis are largely unknown.
Aging is defined as a progressive decline of intrinsic physiological functions,
resulting in an increased risk of death (5). Considering that aging is one of the key risk
factors associated with many chronic diseases, slowing aging is of great importance to
prevent age-associated diseases and improve the health span of life (6). A previous study
reported that chicoric acid extend lifespan in Caenorhabditis elegans (7), its effects on
aging-related phenotypes and its underlying mechanisms, however, remain to be
determined.
Type 2 diabetes mellitus (T2DM) has been recognized as a major public health
challenge throughout the world in recent decades (8, 9). Impaired glucose uptake in
muscle tissues is the primary associated with hyperglycemia in T2DM (10). Previous in
vitro studies reported that chicoric acid ameliorated insulin resistance in human hepatoma
cells (11). However, the effects of chicoric acid on muscle cells and its underlying
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mechanism are still unclear. Here, C2C12 myotubes, derived from murine skeletal
muscle cells and a C57BL/6J mice model were used to determine the role of chicoric acid
on glucose homeostasis and its underlying mechanisms were determined.
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CHAPTER 2
LITERATURE REVIEW
2.1

Chicoric acid
Chicoric acid, a hydroxycinnamic acid that is a member of the phenylpropanoid

family, contains two caffeoyl units (2). Chicoric acid mainly presents in two forms: first,
the most abundant natural form of chicoric acid is L-chicoric acid (Figure 1); second, the
acid presents in the stereoisomer meso-chicoric acid (i.e., dicaffeoyl-meso-tartaric acid or
di-E-caffeoyl-(2R-3S)-(-)-tartaric acid) (1).
Chicoric acid is present in the roots of a large number of plants (63 genera and
species), including many plants grown in the Mediterranean area (1), and many of these
plants have been consumed as alternative medicines or food supplements for some time
(2, 3). Because chicoric acid is found in especially high amounts in chicory (Cichorium
intybus), purple coneflower (Echinacea purpurea), and basil, the acid is often used as a
marker for the quality check of herbal products from these plants (4). The roots of
chicory and purple coneflower are usually baked, grounded and used as a coffee
substitute in Europe (12). In Turkey, an herbal tea made from chicory has been used
historically for the treatment of diabetes, epilepsy, hemorrhoids, inflammation and
digestive disorders (13). The plant roots containing chicoric acid have been used in Asian
traditional medicine as a tonic for curing infectious diseases, inflammatory diseases, eye
diseases, and nerves injuries (13, 14). Commercial products made from purple
coneflower are currently popular alternative medicines widely used in North America for
cold and flu prevention (15). More recently, an increasing number of publications have
reported the beneficial effects of chicoric acid in cell culture and animal studies. This
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review summarizes these health benefit studies and the underlying mechanisms of
chicoric acid.

Figure 2.1. Molecular structure of L-chicoric acid. The most abundant natural form of
chicoric acid is L-chicoric acid, i.e., (-)-chicoric acid, 2,3-dicaffeoyl-L-tartaric acid, 2,3O-dicaffeoyltartaric acid, 2R,3R-O-dicaffeoyltartaric acid, or di-E-caffeoyl-(2R-3R)-(-)tartaric acid.

2.2

The Biological effects of chicoric acid
The main benefits of chicoric acid include antivirus, anti-inflammation, glucose

and lipid homeostasis, neuroprotection, and anti-oxidation effects. Biological activities
and related mechanisms of chicoric acid from in vitro and in vivo studies are summarized
in Tables 1 and 2.

2.2.1

Anti-viral effects of chicoric acid
The first reported bioactive effect of chicoric acid is its ability to inhibit infection

with human immunodeficiency virus 1 (HIV-1) (16). Several studies reported that
chicoric acid inhibits infection with HIV-1 by deactivating HIV-1 integrase (16-23).
HIV-1 integrase is a multidomain enzyme required for the integration of viral DNA into
the host genome, a critical step in viral replication (24). The inhibition of HIV-1
integration by chicoric acid results in the stopping virus replication, leading to increased
T-lymphoblastoid cell viability (17-19, 21, 22). It has been further suggested that chicoric
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acid decreases integrase binding site activity, including: the downregulation of HIV 3'end processing products (16), the occupation of HIV-1 integrase catalytic core (20), the
chelation of integrase divalent cations (17), the increase of long terminal repeat circle
formation (21), and the inhibition of integrase-mediated catalysis (18). Hu et al. (25)
reported that the mutation of HIV integrase might result in the blocking of chicoric acid
specific binding sites and King et al. (26) further reported that the mutation on glycine to
serine at position 140 (G140S) of HIV integrase reduced chicoric acid’s effects on HIV
infection, suggesting that the integrase G140S might be a target site of chicoric acid.
There are a few studies that are using new computational techniques including molecular
docking and quantitative structure-activity relationship (QSAR) analysis to identify the
binding sites of chicoric acid with HIV-1 integrase (25, 27, 28). Chicoric acid binds HIV1 integrase at its two arms, including the s-cis/s-cis isomer and s-cis/s-trans isomer
arrangements (27). Based on the observation that the s-cis/s-cis isomer exhibits the most
stable binding, this site was suggested to be the target of chicoric acid to inhibit HIV
integrase. Another study using QSAR analysis indicated that the poly aromatic rings of
chicoric acid are central linkers in binding to HIV-1 integrase (28). In addition to
integrase, reverse transcriptase is another potential target of chicoric acid (23, 29), as
chicoric acid downregulates reverse transcriptase of HIV-1 through the inhibition of the
trans-activator of transcription, an important protein promoting HIV-1 reverse
transcription (29).
Although chicoric acid may be a potential treatment for HIV, there are several
limitations of using naturally occurring chicoric acid as a treatment, such as poor stability
and limited cell permeability due to diacid moiety (30). To overcome these limitations,
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chicoric acid analogs have been introduced, such as an analog of a decarboxyl compound,
while extending a caffeoyl group on 3,4,5-trihydroxycinnamoyl sidechains, which
showed improved stability and cell bioavailability (30-32). This analog also exhibited the
high potency against HIV integrase infectivity (30-32).

2.2.2

Chicoric acid and inflammatory responses
Chicoric acid has been found to ameliorate inflammation induced by

lipopolysaccharides (LPS) in both cell culture and mice. Reduced inflammation was
associated with down-regulations of nuclear factor κB (NF-κB) and tumor necrosis factor
α (TNF-α) (33-36), which are two major regulators of inflammation responses (37-39).
Several other pro-inflammatory factors – including nitric oxide synthase (iNOS),
cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), interleukin-1β (IL-1β), IL-12 and
IL-18 have been also reported to be downregulated by chicoric acid (33, 35, 40-43).
However, two relevant studies showed results inconsistent with the above. Matthias et al.
(44) reported that LPS inhibited NF-κB expression, which was reversed by chicoric acid
treatments in Jurkat E6.1 leukaemic T-cell lymphoblasts. The other reported that
echinacea extracts (containing chicoric acid) upregulated LPS-induced TNF-α in rat
alveolar macrophages (45). Inconsistencies may be due to dosage and types of LPS used
(i.e., 0.1 vs. 1 μg/ml) (34, 43, 46-48) and/or other components present in treatments (36,
49). Overall, since the pro-inflammatory factors above are related to the occurrence of
many chronic diseases, most research suggests chicoric acid may be considered a
preventive tool for inflammation-associated diseases (33, 35, 40-43), however, further
evaluation is needed.
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2.2.3

Chicoric acid and glucose metabolism
Chicoric acid has been reported to promote glucose uptake in muscle cells and

hepatocytes, through activating the insulin receptor substrate/ phosphoinositide 3-kinase
/protein kinase B (Akt) pathway (11, 50, 51). Zhu et al.(51, 52) suggested that chicoric
acid activated Akt via the AMP-activated protein kinase α (AMPKα)-dependent
mechanism, which is a master regulator for energy homeostasis and also plays a key role
in glucose metabolism. However, the mechanism underlying how chicoric acid induces
AMPKα activation is not known currently. In addition to AMPKα, glucosidase, a
digestive enzyme for carbohydrates, was reported to be suppressed by chicory (53),
which can contribute to reduced glucose levels (54, 55). Another enzyme, protein
tyrosine phosphatase 1B (PTP1B) negatively regulates the insulin signaling pathway by
inhibiting the activity of insulin receptor kinase (56). Two studies with molecular
docking showed the molecular interactions between the allosteric site of PTP1B and
chicoric acid, which suggests chicoric acid might inhibit PTP1B and further activate the
insulin signaling pathway (57, 58).
In in vivo studies, chicoric acid (or leafy extracts of echinacea or basil) reduced
streptozotocin induced-hyperglycemia in mice (50, 52, 59, 60). In these studies, the
protection of pancreatic β-cells by chicoric acid was attributed to its regulation of
apoptosis related-genes, including c-Jun N-terminal kinase (JNK), B-cell lymphoma 2associated X/B-cell lymphoma 2 (Bax/Bcl-2) ratio, and pancreatic duodenal homeobox 1
(PDX-1) (61). In addition, as stated in the previous section, chicoric acid downregulates
several pro-inflammatory cytokines and mediators and these metabolic inflammatory
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cytokines are related to the impairment of glucose homeostasis (62), indicating that
chicoric acid might improve glucose homeostasis via regulating inflammatory responses,
including those associated with regulators COX-2, mitogen-activated protein kinase
(MAPK), cAMP response element binding protein (CREB) and NF-κB (51, 52),

2.2.4

Chicoric acid and lipid metabolism & liver function
Chicoric acid has been found to reduce high-fat-diet-induced weight gain in mice

(63, 64). This was in part via the inhibition of peroxisome proliferator-activated receptorγ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα), two critical transcription
factors in adipocyte differentiation and lipid accumulation, while increasing the secretion
of adiponectin (64). Similarly, a few studies suggested that chicoric acid protected the
liver from high-fat- or alcohol-induced fat accumulation and hepatic steatosis (63-65).
The hepatoprotective effects of chicoric acid were suggested to be due in part to a
decrease in the Bax/Bcl-2 ratio and the inhibition of fatty acid synthase (FAS) and proinflammatory cytokines, including TNF-α, IL-6, COX-2 and JNK in the liver (63, 64).

2.2.5

Chicoric acid and brain function
There is a report that chicoric acid treatment ameliorated restraint stress-induced

behavioral despair and depression in mice (66). This neuro-protective effects of chicoric
acid may result from its upregulation of neurotransmitters, including noradrenaline,
dopamine, and 5-hydroxy tryptamine in the whole brain region of mice (66). Since
restraint stress is an important factor contributing to disorders and behavioral changes
(such as depression, memory loss, anxiety, and learning disability), the possible

8

alleviation of restraint stress by chicoric acid suggests the potential application of
chicoric acid for the above-mentioned brain disorders (66). Others reported that chicoric
acid protected neurons from memory impairment, amyloidogenesis, and hippocampus
shrinkage induced by LPS and D-galactose in mice (33, 34, 67). They also found that
chicoric acid inhibited the expression of amyloid β and its downstream enzyme, neuronal
β-secretase 1, both of which are known factors contributing to the disruption of neural
connectivity and neuronal death (68). Meanwhile, chicoric acid upregulated brain-derived
neurotrophic factor, which is a canonical nerve growth factor supporting the survival of
existing neurons and promoting the growth of new neurons and synapses (69). Although
limited, these findings suggest the potential protective activity of chicoric acid on
controlling the pathogenesis of neuro-degenerative diseases.

2.2.6

Anti-oxidative stress effects of chicoric acid
Oxidative stress is defined as the imbalance between the generation of reactive

oxygen species (ROS) and a physical ability of detoxification or damage restoration
associated with ROS (70). ROS could act as cellular massagers but cause physical
damages through disruptions of normal cell signaling pathways (71). Chicoric acid has
been found to have a high oxygen radical scavenging capacity, reducing the ROS level
and protecting cells from free radical-induced cytotoxicity (34, 53, 72-75). Moreover,
chicoric acid increased the generation of anti-oxidative enzymes that contribute to the
reduction of ROS levels, i.e., glutathione, glutathione peroxidase, superoxide dismutase,
chloramphenicol acetyl transferase, heme oxygenase and NAD(P)H dehydrogenase in
various cells (15, 21, 25, 43, 49, 61, 62, 71, 76, 77). The underlying mechanism of the

9

antioxidative effects of chicoric acid is attributed to the enhanced nuclear translocation of
nuclear factor erythroid 2-related factor 2 (Nrf-2) and the level of peroxisome
proliferator-activated receptor-γ coactivator α (PGC-1α) (34, 73, 75). The activation of
Nrf-2 and PGC-1α inhibit ROS-induced cytotoxicity by upregulation of antioxidant
response-related genes and promotion of the mitochondrial antioxidant defense system,
respectively (78, 79). Since oxidative stress is closely related to the development of
certain cancers and chronic diseases, all these findings suggest the potential future
application of chicoric acid for oxidative stress-associated diseases.

2.2.7

Other bioactivities of chicoric acid
Chicoric acid at relatively higher concentrations (105-315 μM) has been reported

to inhibit cancer cell growth via inhibiting cell proliferation, promoting cell apoptosis,
and deactivating telomerase through upregulation of DNA fragmentation, cleaved
caspase-9, and cleaved poly (ADP-ribose) polymerase (80).
Another study suggested that chicoric acid ameliorated ultraviolet A irradiationinduced dermal fibroblast senescence by the inhibition of matrix metalloproteinase-3
activity (81). As dermal fibroblast senescence is a hallmark of intrinsic and ultravioletmediated aging (77), this indicates the potential role of chicoric acid in aging.
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Table 2.1 In vitro effects of chicoric acid in the treatment of various disorders.
Disorders
Models
Dose Duration
Effects
(µM) (hrs)
Anti-viral
H9 & MT-2 human T1.05- 48
↑ infected cell viability;
effects
lymphoblastoid
10.5
↓ HIV-1 integrase
activity

Suggested mechanisms

References

↓ HIV 3'-end processing
products

(16)

H9 & MT-2 human Tlymphoblastoid

0.4

48

↓ HIV-1 integrase
activity

↓ HIV integrase catalytic
core

(20)

MT-2 human Tlymphoblastoid

105

48

↓ HIV-1 reverse
transcriptase activity

↓ HIV-1 envelope
glycoprotein 120

(29)

MT-2 human Tlymphoblastoid

0.4

72

N/A

(23)

MT-2 human Tlymphoblastoid
MAGI human cervical
epithelial carcinoma
H9 & MT-2 human Tlymphoblastoid

25

72

N/A

(19)

100

52
24

↓ HIV-1 Tat protein
synthesis
↑ integrase divalent
cations chelation

(82)

0.110

MT-4 human T-

70

2

↑ infected cell viability;
↓ HIV-1 reverse
transcriptase activity; ↓
HIV-1 reverse
transcriptase release
↓ HIV-1 integrase
replication
↓ HIV-1 integrase
activity;
↓ viral replication;
↓ HIV-1 integrase
activity
↓ viral replication cycle;

↓ HIV-1 envelope

(83)

11

(17)

lymphoblastoid

Glucose
metabolism

↓ viral entry

glycoprotein 120

↑ infected cell viability;
↓ HIV-1 integrase
activity
↓ HIV-1 integrase
activity
↓ HIV-1 integrase
activity
↑ glucose uptake;
↑ insulin secretion

↑ long terminal repeat
circle formation

(21)

↓ integrase binding site
activity
↓ integrase-mediated
catalysis
N/A

(22)

MT-2 human Tlymphoblastoid

4.2

72

H9 & MT-2 human Tlymphoblastoid
H9 & MT-2 human Tlymphoblastoid
L6 rat myotubes &
insulinoma-derived ISN1 pancreatic β cells

50

1-4

25

1

200
&
20100

1-2

INS-1 pancreatic βcells; L6 myotubes;
isolated hepatocytes
(rat)
HepG2 human
hepatoma

105210

1-3

↑ glucose uptake;
↑ insulin secretion

N/A

(50)

100

24

↓ insulin resistance;
↓ NO & ROS

(51)

HepG2 human
hepatoma

100

24

↑ glucose uptake

4.2

4

N/A

↑ GLUT2 translocation;
↑ Akt; ↓ MAPK; ↓ NFκB
↑ IRS-1; ↑ Akt; ↑
AMPKα; ↑ SIRT1; ↑
GSK-3β; ↓ CREB
↓ NF-κB; ↓ TNF-α

N/A
17

N/A
4

↓ cell inflammation
N/A

↓ TNF-α
↑ NFκB

(35)
(44)

Inflammation RAW 264.7 mouse
responses
macrophage
Macrophage
Jurkat E6.1 human

12

(18)
(11)

(52)

(36)

Oxidative
stress

leukemic T-cell
lymphoblast
Mouse peripheral blood
mononuclear cells
BV-2 mouse microglia

0.54.2
80

4

↑ immune homeostasis

↑ IL-2; ↑ IFN-γ; ↓ IL-4

(41)

4

↓ cell inflammation

(33)

Human umbilical vein
endothelial cells

12.5100

24

HT-29 human colorectal
adenocarcinoma
Human plasma

42

12

↓ endothelial
dysfunction; ↓ cell
apoptosis; ↑ cell
viability; ↓ ROS
↓ cell inflammation

1

5

↓ iNOS; ↓ COX-2; ↓
PGE2; ↓ IL-1β; ↓ TNF-α
↑ SOD; ↑ eNOS; ↓
Bax/Bcl-2; ↓ cleaved
caspase-3; ↓ MAPK; ↓
NF-κB
↓ NF-κB; ↓ COX-2; ↓
IL-1β; ↓ IL-18
N/A

RAW264.7 mouse
macrophage
RAW264.7 mouse
macrophage
L6 rat myotubes

1632
N/A

20

(47)

5-50

1

RGC-5 rat retinal
ganglion cells
RAW264.7 mouse
macrophage
HepG2 human
hepatoma
Daudi & Namalwa B
lymphocyte; JeKo-1

0.025 24

↓ PGE2; ↓ TNF-α; ↓ IL1β; ↓ NF-κB; ↓ Akt
↑ GSH; ↓ iNOS; ↓ NFκB
↑ GPx; ↑ SOD; ↑ pAMPKα; ↑ PGC-1α
↓ cleaved PARP; ↓
cleaved caspase-3
↓ MyD88; ↓ iNOS; ↓
TNF-α
↓COX-2; ↓iNOS; ↓ NFκB
↓ NF-κB; ↓ IκB

20

↓ Cu (II)-catalyzed LDL
oxidation
↓ oxidative stress
↓ oxidative stress & ↓
NO
↓ ROS

340

19

↑ cell viability &
↓ ROS
↓ oxidative stress

100

24

↓ NO; ↓ ROS

21105

12-48

↓ B cell activating factor
belonging to the TNF

13

(42)

(43)
(84)

(48)
(73)
(67)
(65)
(51)
(85)

mantle cell lymphoma,
THP-1 monocytes &
HepG2 hepatoma
(human)
BV-2 mouse microglia

Others

family (BAFF)

80

4

↓ oxidative stress

(34)

↑ infected cell viability;
↓ HBV activity

↓ NF-κB; ↓ MAPK; ↑
Nrf2
↑ Nrf2; ↑ HO-1; ↑ NQO1; ↑ CAT; ↑ GSH; ↓
TNF-α; ↓ IL-1β; ↓
malondialdehyde
↓ HBV surface &
envelope antigen

SH-SY5Y human
neuroblastoma

50

24

↓ oxidative stress;
↑ cell viability

HL-7702 human
hepatocytes & HepG2
human hepatoma
Caco-2 & HCT-116
epithelial colorectal
adenocarcinoma
(human)
HeLa cervical
carcinoma & MCF-7
breast carcinoma
(human)
Human skin fibroblasts

20200

48

105315

24-48

↓ cell proliferation;
↑ cell apoptosis;
↓ telomerase activity

↑ DNA fragmentation; ↑
cleaved caspase-9; ↑
cleaved PARP

(80)

0.05

24

↓ doxorubicin-induced
cell death

N/A

(87)

2

24

↓ MMP-3

(81)

3T3-L1 mouse
preadipocytes

100

48

100

24

↑ cleaved caspase-3;
↓ Akt; ↑ MAPK; ↓ JNK
& ERK1/2
N/A

(64)

3T3-L1 mouse
preadipocytes

↓ dermal fibroblasts
senescence
↑ cell apoptosis & ↓
mitochondrial membrane
potential
↑ free radical scavenging

14

(75)

(86)

(76)

↑ - increase; ↓ - decrease; N/A, not available.
Acronyms: Akt, protein kinase B; AMPKα, AMP-activated Protein Kinase α; Bax/Bcl-2, B-cell lymphoma 2-associated X/B-cell
lymphoma 2; BSO, 1-buthionine-(S,R)-sulfoximine; CREB, cAMP response element binding binding protein; CAT, chloramphenicol
acetyl transferase; COX-2, cyclooxygenase-2; eNOS, endothelial nitric oxide synthase; ERK1/2, extracellular signal–regulated kinase
1/2; GLUT2, glucose transporter 2; GPx, glutathion peroxidase; GSH, glutathione; GSK-3β, glycogen synthase kinase 3β; HBV,
hepatitis B virus; HIV-1, human immunodeficiency virus 1; 4-HNE protein adducts, 4-hydroxynonenal-protein adducts; HO-1, heme
oxygenase; IFN-γ, interferon γ; IĸB, inhibitor of kappa B; IL-1β, interleukin 1 beta; iNOS, nitric oxide synthase; IRS-1, insulin
receptor substrate 1; JNK, c-Jun N-terminal kinase; LPS, lipopolysaccharides; MAGI, HeLa CD4+ HIV-1 LTR-β-gal cells; MAPK,
mitogen-activated protein kinase; MMP-3, matrix metalloproteinase-3; MyD88, myeloid differentiation primary response 88; NF-κB,
nuclear factor κB; NQO-1, NAD(P)H dehydrogenase; Nrf2, nuclear factor erythroid 2–related factor 2; LDL, low-density lipoprotein;
PARP, poly (ADP-ribose) polymerase; PGC-1α, peroxisome proliferator-activated receptor-γ coactivator α; PGE2, prostaglandin E2;
ROS, reactive oxygen species; SIRT1, sirtuin 1; SOD, superoxide dismutase; Tat, trans-activator of transcription; TNF-α, tumor
necrosis factor α.
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Table 2.2 In vivo effects of chicoric acid in the treatment of various disorders.
Diseases
Species
Models
Dose
Duration
(sex)
(mg/kg/d)
(days)
Brain
Swiss albino
Restraint stress
1-2 p.o.
14
function
mice (M)
(Porsolt's swim
stress & conical
polypropylene
tubes)
Sprague−Dawley Retinal damage
2 μg/eye
7
rats & ICR mice (N-methyl-Dintravitreal
(M)
aspartate / optic injection
nerve crush)
C57BL/6J mice
LPS challenges
0.5 g/L
45
(M)
drinking
water

Glucose
metabolism

Effects

Suggested
Mechanisms
↓ behavioral
↑ norepinephrine;
despair;
↑ dopamine; ↑ 5↑ learning ability;
hydroxy
↑ neurotransmitters tryptamine

(66)

↑ retinal ganglion
cell viability

↓ cleaved PARP; ↓ (67)
cleaved caspase-3

↓ memory
impairment; ↓
amyloidogenesis

↓ amyloid β (Aβ142);
↓ BACE1; ↓
MAPK; ↓ NF-κB
↓ MAPK; ↓ NFκB; ↓ iNOS; ↓ IL1β; ↓ TNF-α; ↑
Nrf2; ↑ HO-1; ↑
NQO-1
↓ amyloid β (Aβ142); ↑ BDNF

(33)

N/A

(50)

N/A

(59)

C57BL/6J mice
(M)

LPS challenges

0.5 g/L
drinking
water

45

↓ oxidative stress
induced neuron
damage

C57BL/6J mice
(M)

D-glactose
challenges

100 i.p.

56

Wistar rats (M)

No challenge

3-30 i.p.

4

Swiss mice (M)

Streptozotocin
challenge

3 i.p.

2 hrs

↓ neuron damage;
↓ hippocampus
shrinkage
↑ insulin secretion;
↓ hyperglycemia
↓ hyperglycemia
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References

(34)

(75)

Lipid
metabolism
& liver
function

Swiss mice (M)

Streptozotocin
challenge

1-3
i.p.

2 hrs

↓ hyperglycemia

N/A

(60)

C57BL/6J mice
(M)

Streptozotocin
challenge

60 drinking
water

4

↓ JNK; ↓ Bax/Bcl2; ↑ PDX-1

(61)

C57BL/6J mice
(M)

High-fat diet
challenge

15-60 p.o.

8

↓ hyperglycemia; ↓
pancreas
apoptosis; ↑
insulin secretion
↓ body weight; ↓
hepatic steatosis

C57BL/6J mice
(F)

Hepatic steatosis
(alcohol)

4 drinking
water

4

↓ hepatic
triacylglycerols

C57BL/6J mice
(M)

Methionine- and
choline-deﬁcient
diet challenge

10-30 p.o.

4

C57BL/6J mice
(M)

Streptozotocin
challenge

60 drinking
water

28

↓ hepatic lipid
accumulation; ↓
lipid peroxidation;
↓ hepatic
ballooning,
steatosis &
inﬂammation
↓ hepatic injury

LPS challenge

20 p.o.

4

↑ phagocytic

Inflammation Sprague-Dawley
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↓ TNF-α; ↓ IL-6; ↓ (64)
COX-2; ↓ JNK; ↓
PPARγ; ↓
C/EBPα; ↓ FAS; ↓
ALT & AST
↓ iNOS; ↓ 4-HNE (65)
protein adducts; ↓
TNF-α; ↓ PAI-1; ↓
CD11c
↓ SREBP-1c; ↑
(63)
Nrf2; ↑ AMPK; ↓
TNF-α; ↓ MCP-1;
↓ FAS; ↓ ALT &
AST
↑ glycogen; ↑
(52)
glycolysis genes
(Gck, Pk & Pfk); ↑
AMPK
↑ TNF-α; ↑ IFN-γ (45)

rats (M)
Swiss albino
mice (M)

Restraint stress
(conical
polypropylene
tubes)

2 p.o.

14

Sprague-Dawley
rats (M)

Arthritis
(collagen)

8-32 p.o.

28

ICR mice (M)

Anaphylactic
shock
(compound
48/80)

20 p.o.

2 hrs

activity; ↑ NO
↑ Th1/Th2
homeostasis;
↑ lymphocyte
proliferation & T
cell population
[cluster
determinant 3 (+),
4(+) & 8(+)]
↓ paw swelling; ↓
organ index of the
thymus and spleen
↓ mortality rate; ↓
histamine levels in
blood serum

↑ CD28 & CD80;
↓ CTLA-4; ↓
CD152; ↓ IL-10; ↑
IFN-γ; ↑ IL-2; ↑
IL-12

(88)

↓ NF-κB; ↓ TNFα; ↓ COX-2

(40)

N/A

(89)

M – male; F - female; ↑ - increase; ↓ - decrease; N/A, not available; p.o., Per os (oral administration); i.p., intraperitoneal injection.
Acronyms: Akt, protein kinase B; ALT, alanine aminotransferase; AMPKα, AMP-activated Protein Kinase α; AST, aspartate
aminotransferase; BACE1, neuronal β-secretase 1; Bax/Bcl-2, B-cell lymphoma 2-associated X/B-cell lymphoma 2; BDNF, brainderived neurotrophic factor; CD11c, integrin α X chain protein; CD28, cluster of differentiation 28; CD80, cluster of differentiation 80;
CD152, cluster of differentiation 152; C/EBPα, CCAAT/enhancer binding protein α; COX-2, cyclooxygenase-2; FAS, fatty acid
synthase; CTLA-4, cytotoxic T-lymphocyte associated antigen 4; 4-HNE protein adducts, 4-hydroxynonenal-protein adducts; HO-1,
heme oxygenase; IFN-γ, interferon γ; IL-1β, interleukin 1β; iNOS, nitric oxide synthase; JNK, c-Jun N-terminal kinase; Keap1, kelchlike ECH-associated protein 1; LPS, lipopolysaccharides; MAPK, mitogen-activated protein kinase; MCP-1, monocyte
chemoattractant protein 1; NF-κB, nuclear factor κB; Nrf2, nuclear factor erythroid 2–related factor 2; NQO-1, NAD(P)H
dehydrogenase; PAI-1, plasminogen activator inhibitor-1; PARP, poly (ADP-ribose) polymerase; PDX-1, pancreatic duodenal
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homeobox 1; PPAR γ, peroxisome proliferator activated receptor γ; ROS, reactive oxygen species; SREBP-1, sterol regulatory
element-binding protein 1; TNF-α, tumor necrosis factor α; Th1/Th2, T helper cells 1/2.
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2.3 Suggested molecular targets of chicoric acid
As discussed in previous sections, chicoric acid modulates genes, transcription
factors, growth factors, enzymes, and proteins involved in important cellular processes,
such as virus infection, chemoresistance, inflammation, and glucose metabolism (Figure
2.2) (11, 42, 82, 85). Among them, it is suggested that NF-κB and TNF-α are two major
mediators of chicoric acid’s activities.
NF-κB is a protein complex involved in cellular responses to stress, free radicals,
heavy metals, and bacterial or viral infections through regulating DNA transcription,
cytokine production, and cell survival (37, 38, 90). It is known that the activity of NF-κB
is directly suppressed by binding with the inhibitor of κB (IκB) in the cytoplasm (90). In
contrast, the phosphorylation of IκB releases and activates NF-κB (90). Chen et al. (85)
reported that chicoric acid deactivates NF-κB by inhibiting the phosphorylation of IκB,
indicating that IκB may be a major regulator for chicoric acid-mediated inactivation of
NF-κB. Alternatively, NF-κB can be activated in combination with TNF-α (37). Several
studies reported that chicoric acid decreased TNF-α production (40, 47, 64, 65, 75),
which might be a contributing factor to the reduced activation of NF-κB. Chicoric acidrelated deregulations of NF-κB and TNF-α were shown to alleviate conditions such as
autoimmune disorders, restraint stress, hepatic steatosis and neuron damage known to be
involved in cellular inflammation and associated diseases (34-36, 40, 47, 63-65, 75).
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Figure 2.2 Molecular targets of chicoric acid. Akt, protein kinase B; ALT, alanine aminotransferase; AMPKα, AMP-activated Protein
Kinase α; AST, aspartate aminotransferase; BACE1, neuronal β-secretase 1; Bax/Bcl-2, B-cell lymphoma 2-associated X/B-cell
lymphoma 2; BDNF, brain-derived neurotrophic factor; CD28, cluster of differentiation 28; CD80, cluster of differentiation 80;
CD152, cluster of differentiation 152; C/EBPα, CCAAT/enhancer binding protein α; COX-2, cyclooxygenase-2; ERK1/2,
extracellular signal–regulated kinase 1/2; FAS, fatty acid synthase; HO-1, heme oxygenase; GLUT2, glucose transporter 2; IFN-γ,
interferon γ; IL-1β, interleukin 1β; iNOS, nitric oxide synthase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein
kinase; MCP-1, monocyte chemoattractant protein 1; NF-κB, nuclear factor κB; Nrf2, nuclear factor erythroid 2–related factor 2;
NQO-1, NAD(P)H dehydrogenase; PARP, poly (ADP-ribose) polymerase; PDX-1, pancreatic duodenal homeobox 1; PPAR γ,
peroxisome proliferator activated receptor γ; SREBP-1, sterol regulatory element-binding protein 1; TNF-α, tumor necrosis factor α;
Th1/Th2, T helper cells 1/2.
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2.4

Pharmacokinetic study of chicoric acid
Chicoric acid is known to have relatively low absorption in rats (91). The oral

administration of chicoric acid at 50 mg/kg body weight resulted in a peak plasma
concentration of chicoric acid at 1.63 ±0.25 mg/L after 4 h (91). Chicoric acid was
mainly distributed in the liver, lung and kidney after oral administration for 3 h. Chicoric
acid has a relatively long residence time and low body clearance, 18.58 ± 4.43 h and 2.80
±0.46 L/kg/h, respectively, in rats (91). All these findings help in better understanding
the bioavailability and fate of chicoric acid.

2.5

Conclusion
The prevention of early-stage chronic diseases by food bioactive seems to be a

promising strategy. Chicoric acid’s multi-bioactivities suggest it has great potential in
treating a number of metabolic disorders, including inflammatory responses, impairment
of energy homeostasis, brain dysfunction, and immune disorders. Even though there are
increasing number of studies reporting bioactivities of chicoric acid, these are still
limitations to make a concrete conclusion due to differences on models, doses, and
treatment durations used, as well as lack of pharmacokinetic study, including metabolism,
of chicoric acid in humans. The research on chicoric acid is still at an early stage, so there
are still many questions that need to be answered regarding its benefits to health. Thus,
more studies are needed to guide the development of chicoric acid-based functional food
products.
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CHAPTER 3
OBJECTIVES OF THE PROJECT
The long-term goal is to develop chicoric acid as a functional food bioactive for
the prevention and/or treatment for aging and type 2 diabetes. Previous studies reported
that chicoric acid extends C. elegans lifespan and promotes glucose transport in hepatic
cells (7). However, more experiments are needed to further investigate the effects of
chicoric acid on aging-related phenotypes in C. elegans and the glucose uptake in other
models. The object of this project is to determine the effect of chicoric acid on the agingassociated phenotypes of C. elegans and glucose uptake in muscle cells. The central
hypothesis is that chicoric acid can protect C. elegans during aging as well as promote
glucose uptake in muscle cells. The rationale of the proposed research is that by
investigating the effect of chicoric acid on aging and glucose uptake as well as the
underlying mechanisms, we will be able to better understand chicoric acid as a beneficial
bioactive for the promotion of health span and prevention from type 2 diabetes.
The project aims are as follows:
Specific aim 1: Determine the effect of chicoric acid on aging and aging-related
phenotypes of C. elegans. The hypothesis is that chicoric acid extends the lifespan of C.
elegans and delays the decrease of aging-related phenotypes.
Specific aim 2: Investigate the effect of chicoric acid on glucose uptake in muscle
cells and mice. The hypothesis to be tested is that chicoric acid promotes the glucose
uptake in C2C12 myotubes and reduces the blood glucose level in mice.
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CHAPTER 4
EFFECTS OF CHICORIC ACID ON AGING AND
GLUCOSE UPTAKE
4.1

Effect of chicoric acid on aging in C elegans and the underlying mechanisms

4.1.1

Introduction
Aging is defined as a progressive decline of intrinsic physiological functions,

resulting in an increased risk of death (5). Considering that aging is one of the key risk
factors associated with many chronic diseases, slowing aging is of great importance to
prevent age-associated diseases and improve the health span of life (6). Currently, foodderived bioactive compounds are drawing significant attention because of their anti-aging
effects and the modulation of aging-related pathways (92-95), which provide potentially
valuable preventive tools for aging and aging-related disorders.
Chicoric acid, one of the hydroxycinnamic acids, is a dicaffeoyl ester naturally
found in the roots of many plants, such as chicory, purple coneflower, and basil (4).
Chicoric acid is reported to have a number of bioactivities, including antioxidation, antiinflammation, antivirus and immune-stimulating properties through multiple molecular
pathways (18, 33, 41, 52). A previous study reported that chicoric acid extended the
lifespan in Caenorhabditis elegans (7), however, the effects of chicoric acid on agingrelated phenotypes and the mechanisms underlying these effects remain to be determined.
One recent study reported that chicoric acid regulates glucose metabolism via
AMP-activated protein kinase (AMPK) activation (52). AMPK is an energy sensor that
controls energy homeostasis through the regulation of AMP/ATP metabolism in cells (4).
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Moreover, AMPK is considered important in the regulation of longevity as the increased
activation of AMPK extended the lifespan through dietary restriction and/or enhanced
stress resistance in C. elegans and Drosophila melanogaster (96, 97). aak-2, a homolog
of the α-catalytic subunits of mammalian AMPK, is evolutionarily conserved in both C.
elegans and mammals (98). Since AMPK has been reported to be activated by chicoric
acid (52), it is plausible to assume that chicoric acid might regulate the lifespan of C.
elegans via aak-2. In addition to aak-2, skn-1, encoding a homolog of nuclear factor
erythroid 2–related factor 2 (Nrf-2) in C. elegans, was also reported to extend lifespan by
regulating the oxidative stress response pathway (99). Therefore, the current research
focused on determining the influence of chicoric acid on aging-related phenotypes in C.
elegans and the role of AAK-2 and SKN-1 in this process.

4.1.2

Materials and methods

4.1.2.1 Materials
Chicoric acid (≥ 98%) was purchased from PufeiDe Biotech Co., Ltd (Chengdu,
Sichuan, China). Household bleach used for bleaching adult nematodes during
synchronization was obtained from Clorox company (Oakland, CA, USA).
Fluorodeoxyuridine (FUdR), ampicillin, and carbenicillin, paraquat, and 2’,7’dichlorodihydrofluorescein diacetate (DCFDA) were ordered from Sigma-Aldrich (St.
Louis, MO, USA). Rabbit antibodies for phospho-AMPK and α-tubulin, as well as goat
anti-rabbit IgG-horseradish peroxidase (HRP) were obtained from Cell Signaling
Technology (Danvers, MA, USA). Rabbit antibodies for phospho-AMPK and α-tubulin,
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as well as goat anti-rabbit IgG-horseradish peroxidase (HRP), were obtained from Cell
Signaling Technology (Danvers, MA, USA).

4.1.2.2 C. elegans: strains and maintenance
The strains in the study were provided by the Caenorhabditis Genetics Center
(CGC, University of Minnesota, Minneapolis, MN, USA): wild-type Bristol N2, aak-2
(ok524) X, daf-2 (e1370) III, eat-2(ad1116) II, daf-16(mgDf50) I, skn-1(zu135) IV, age1(hx546), and ldIs7 (skn-1b/c::gfp; rol-6). All strains were grown and incubated at 20 °C
on nematode growth media (NGM) plates with Escherichia coli OP50, except daf-2,
which was maintained at 15 °C. The solutions including nematode growth medium
(NGM), M9 buffer, and S-complete required for C. elegans culture were prepared
according to the worm book (100). A synchronized culture was obtained as previously
described (101). The chicoric acid stock solutions with 12.5, 25, and 50 mM were
prepared using dimethyl sulfoxide (DMSO) as solvent. Stock solutions were diluted 1000
times resulting in final concentrations of chicoric acid at 12.5, 25, and 50 M. These
doses were based on a previous report on the effects of chicoric acid on life span
extension in C. elegans (7). For lifespan analysis, L4 stage nematodes were transferred in
Transwell-96 well plate (Corning Inc., NY, USA; n=10-15 worms per well, 15-18 wells/
treatment) and treated with 0.1% DMSO (control) or chicoric acid during the lifespan
study (94, 102, 103). FUdR (120 mM), to prevent eggs from hatching out, was also added
(104). The medium was changed every four days. The survivals were determined by a
gentle touch-prod with a sterilized picker under a microscope (Nikon Instruments Inc.,
Melville, NY, USA) (94, 103). Worm viability was recorded every other day until all
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worms died. The day that the treatment began is considered as day 0. The lifespan test in
N2 was repeated for three independent trials.

4.1.2.3 Growth rate, body size, and moving speed determination
The growth rate of C. elegans was determined by quantifying the population of
worms at three different developmental stages after 48 h chicoric acid treatments. Results
were shown in percent of proportion of C. elegans in each stage (94). Body size and
moving speed of C. elegans were measured by the WormLab tracking system (Allied
Vision Technologies, Stadtroda, Germany) and analyzed by WormLab Software (MBF
Bioscience, Williston, VT, USA) as published (101). Worms were transferred to the lowpeptone NGM plates seeded with OP50 and were undisturbed for 30 min for acclimation
before tracking (94). A 1-min recording (8.12 frames per second) was captured. The size
of the worms (70-90/treatment) was measured by the WormLab Software after 48 h of
treatments. The moving speed of worms was measured every other day from day 2 to day
12.

4.1.2.4 Progeny production and pumping rate determination
After 48 h chicoric acid treatments, two L4 staged nematodes/treatment were
shifted to freshly prepared NGM plates with E. coli OP50 every day during the
reproduction period. The number of progeny hatching out of eggs was counted and
recorded daily (94). The pumping rate was obtained by quantifying pharyngeal
contraction times of nematodes using a microscope (Olympus Corporation, Tokyo, Japan)
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for 30 sec. The test was repeated three times with 12 randomly-selected nematodes per
treatment (94).

4.1.2.5 Measurement of intracellular ROS and oxidative stress resistance
The intracellular reactive oxygen species (ROS) level was detected using
DCFDA, a fluorescent probe commonly applied for ROS detection (105). After a 72-h
treatment with DMSO (control group) or chicoric acid, day 1 adult nematodes were
washed with M9 buffer three times to remove bacteria. They were next transferred into a
96-well plate, ~60 worms/well, with or without chicoric acid treatments in 50 µL of M9
buffer, following the mixture of 50 µL DCFDA solution (200 µM) to achieve 100 µM of
the final concentration. A well with 100 µM DCFDA solution with no worms was used as
the background, and worms treated with DCFDA solution and 5 mM paraquat were used
as the positive control. The fluorescent readings were taken after 30 min of incubation at
an emission/excitation wavelength of 530 and 485 nm by an Infinite 200 PRO microplate
reader (Tecan Trading AG, Switzerland).
For oxidative stress resistance determination, day 1 adult worms were transferred
into the 96 trans-well plate, 12-15 worms per well, containing 5 mM paraquat, an
oxidative stress inducer. The oxidative stress resistance of C. elegans was determined by
counting the survival percentage of worms under the exposure of paraquat for 2, 4, and 6
days with or without chicoric acid treatment (i.e., 25 µM) (94).

4.1.2.6 Quantitative real-time PCR
RNA was extracted in each sample using Trizol under RNase-free conditions, as
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previously described (101). cDNA was prepared by reverse transcription of mRNA using
a high-capacity cDNA reverse transcription kit (Thermo Fisher Scientific Inc,
Middletown, VA, USA). The gene expression was quantified by QuantStudio 3 real-time
PCR system using the TaqMan detection assay (Applied Biosystems, Waltham, MA,
USA). aak-2 (Ce02404259_g1), nhr-49 (Ce02412666_g1), skn-1 (Ce02407444_m1), gsr1 (Ce02444754_g1) and pbs-5 (Ce02426103_g1), and the internal control ama-1
(Ce02462726_m1) were ordered from Thermo Scientific (Middletown, VA, USA).

4.1.2.7 Intracellular localization of SKN-1::GFP
Transgenic strain ldIs7 (skn-1b/c::gfp; rol-6) was used to detect the intracellular
localization of GFP tagged SKN-1 protein. After two-day of chicoric acid treatment (25
µM), around 10-20 worms (L4 stage or young adults) were placed on each microscope
slide coated with 2% agarose pad and anesthetized with 10 mM NaN3 within 3 min (94).
Worms treated with NaN3 (2%) for 15 min were used as the positive control. The cellular
localizations of SKN-1 were detected by a Nikon Eclipse Ti-U (Nikon Instruments Inc.,
Melville, NY, USA). The nuclear translocation patterns of SKN-1::GFP were identified as
‘low’, ‘medium’, and ‘high’. ‘Low’ refers to worms with almost no visible nuclear
translocation; ‘medium’ refers to C. elegans with nuclear translocation in the partial
body; ‘high’ refers to worms with nuclear translocation throughout the whole body, as
shown in Figure 4.6D. Worms were counted and analyzed as percentages of nuclear
translocation including both ‘medium’ and ‘high’ translocation (103).

4.1.2.8 Western blotting
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The C. elegans protein extraction was obtained according to the protocol
published with minor modification (101, 106). Worms were collected and washed four
times with M9 buffer to remove bacteria. Then worms (approximately 6000 young adults
per sample) were suspended by 500 µL PBS mixed with protease and phosphatase
inhibitors (Beyotime Biotechnology, Shanghai, China). Samples were homogenized and
centrifuged (12,000 × g) at 4 °C for 10 min to harvest the supernatants. After protein
normalization, the samples with 5 × sample buffer were electrophoresed on a 10% SDS
polyacrylamide gel and transferred onto a polyvinylidine fluoride membrane (107). After
blocking with 5% skim milk, the membrane was incubated with rabbit monoclonal antiphospho-AMPK and rabbit anti-α-tubulin antibody. Horseradish peroxidase-conjugated
goat anti-rabbit IgG was used as the secondary antibody. Protein blots were pictured by a
Tanon 5500 image station (Shanghai, China) with ECL Substrate Kit (Bio-Rad Co.,
Hercules, CA, USA). Images were quantified with ImageJ software.

4.1.2.9 Statistical analysis
Survival curves were analyzed by Log-rank (Mantel-Cox) tests by Graph Pad
Prism version 6.0 (GraphPad Software, Inc., San Diego, CA, USA). The data of nuclear
translocation of SKN-1::GFP in Fig. 4.6D was analyzed by chi square tests by SAS
software (version 9.3, SAS Institute Inc., Cary, NC, USA). For other data, differences
between each treatment were analyzed using one-way ANOVA (Tukey’s multiple-range
test, SAS). Significance of differences was defined as P values of < 0.05.

4.1.3

Results
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4.1.3.1 Chicoric acid extended the lifespan of C. elegans
Compared with the control, chicoric acid at 25 and 50 µM, but not 12.5 µM,
significantly extended the lifespan of wild type nematodes (P<0.0001 for both; Fig. 1).
There was no difference in lifespan between 25 and 50 µM chicoric acid treatments.
Table 1 also exhibited the extended median lifespan of wild type N2 worms with 25 and
50 µM chicoric acid treatment, compared to the control. This was consistently observed
from 3 independent experiments: (median lifespan as days) 18.7±0.3 for control,
23.3±0.9 for 25 µM chicoric acid, and 22.7±0.7 for 50 µM chicoric acid with P=0.0062
and P=0.0128 for 25 and 50 µM chicoric acid compared to the control, respectively.
Thus, 25 and 50 µM were used to determine the aging-related phenotypes.

Figure 4.1 Survival of wild-type C. elegans treated with chicoric acid. C. elegans (N2)
were treated with final concentrations of 0 (control), 12.5, 25, or 50 µM chicoric acid
starting from L4 stage (day 0). The survivals were recorded every other day until all the
worms died (n = 206–266/treatment). Log-rank (Mantel-Cox) test was used for statistical
analysis. Significant differences of median/maximum lifespan compared between the
control and the treatment groups were marked as ***P<0.001.

The physiological properties of C. elegans treated by chicoric acid after
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synchronization were determined by growth rate, body size, and progeny (Fig. 4.2). After
48 h of treatment, 76–80% of the nematodes reached L4 stage or young adult stage, while
20–23% were at early/mid L4 stage (Fig. 4.2A). As shown in Fig. 4.2, no difference was
observed in the growth rate, worm length, worm width, or progeny number of C. elegans
treated with or without chicoric acid. The results suggest that the physiological properties
of nematodes were not affected by chicoric acid.

Figure 4.2 Effect of chicoric acid on growth rate, worm size and progeny production of
C. elegans. (A) Synchronized L1 worms were raised on NGM plates with 0, 25 and 50
µM chicoric acid. After 48 h treatments, the number of worms at three developmental
stages was counted and calculated in percent of proportion. (B) Synchronized L1 larval
worms were treated with chicoric acid and the number of progeny hatching out from day
1 to day 5 were recorded. (C) Worm length and (D) width were measured by WormLab
software after 48 h treatments from the L1 stage. Values are means ±S.E. (n = 3 plates
and ~150 worms/plate for growth rate; n = 3 plates and 2 worms/plate for progeny
production, n = 140–180 for worm size).
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4.1.3.2 Effect of chicoric acid on the age-associated decline of phenotypes and ROS
levels
Two typical markers of aging-relative phenotypes in C. elegans are pharyngeal
pumping rate and locomotive activity (102). Thus, we next detected the effects of
chicoric acid on these two markers (Fig. 4.3). The pumping rate as expected declined
progressively with aging: 60% decline of the pumping rate in the control group from day
4 to day 12 (Fig. 4.3). Chicoric acid treatments with both 25 and 50 µM statistically
delayed the decrease of pumping rate compared to the control (Fig. 4.3A). A significant
difference was first observed on day 6, and a greater difference was found on day 12
(29.1% and 32.9% improvement, respectively, compared to the control). Aging resulted
in the decline of moving speed by 76.4% on day 12, compared with that of day 2 in the
control (Fig. 4.3B). Consistent with changes in the pumping rate, the decline in
locomotive activity of the worms was lessened by chicoric acid treatments; On day 12,
chicoric acid-treated C. elegans moved 59% and 86% faster than the control group,
respectively (Fig. 4.3B).

Figure 4.3 Chicoric acid ameliorated the age-related decline of movement and pumping
rate. (A) Synchronized L1 C. elegans were treated with chicoric acid and pharyngeal
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pumping was counted every other day until day 12. (B) Synchronized L1 C. elegans were
treated with chicoric acid and moving speed was recorded by WormLab tracking system.
Then the average moving speed of each worm was calculated using WormLab Software.
Values are means ± S.E. n = 12 worms for pumping rate; n = 140–180 for worm speed.
Values with different letters at each point in time are significantly different (P < 0.05).

Previous studies have reported that extended lifespan is closely associated with
increased resistance towards oxidative stress (93, 94, 96). Since chicoric acid is known to
possess anti-oxidative properties, the intracellular ROS levels of C. elegans were
determined after the treatment of chicoric acid. The intracellular ROS levels in the
chicoric acid treatment groups were significantly reduced (14.6% and 19.2% for 25 and
50 µM chicoric acid with P=0.0392 and P=0.0134, respectively) compared with the
control (Fig. 4.4).

Figure 4.4 Effect of chicoric acid on the oxidative stress sensitivity of wild type N2
worms. Relative formation of reactive oxygen species (ROS) after 72 h of exposure to
chicoric acid (0, 25 or 50 μΜ). Paraquat (5 mM) was used as the positive control. Values
are means ±S.E. (n = 9; 60 worms/well). Values with different letters are significantly
different (P<0.05).
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4.1.3.3 Extended lifespan by chicoric acid required AAK-2 and SKN-1
Several studies reported that aak-2 is an essential regulator in the aging of C.
elegans through dietary restriction and/or stress resistance (96, 108-110). aak-2 encodes a
homolog of the catalytic-α subunit of AMPK in C. elegans. The deletion of aak-2
shortens C. elegans lifespan, while the overexpression of aak-2 results in C. elegans
lifespan extension (108, 109). Since chicoric acid has been found to upregulate AMPK in
hepatocytes (52), we determined the role of AMPK homolog in chicoric acid’s effects on
lifespan extension using aak-2 loss-of function mutants. As shown in Table 4.1 and Fig
4.5A, the deletion of aak-2 abolished chicoric acid-mediated lifespan extension,
indicating the requirement of aak-2 in C. elegans-lifespan extension by this compound.
In addition to aak-2 , it is known that the insulin/IGF-1 signaling pathway is
involved in aging in nematodes (111, 112). daf-2 encodes for the insulin-like growth
factor 1 (IGF-1) receptor, which is an important regulator for aging in nematodes (113).
Mutants deficient in daf-2 exhibit longer lifespan due to an extended dauer stage (114).
One of the downstream targets of daf-2 is age-1, another gene mainly regulating the
longevity of C. elegans (113). Furthermore, DAF-2 and AGE-1 have been reported to
inhibit DAF-16, an important transcription factor that regulates C. elegans’ lifespan (94).
To determine whether chicoric acid extends lifespan through the insulin signaling
pathway, we tested daf-2, age-1, and daf-16 null mutants. The daf-2 deficient and age-1
deficient mutants treated with 25 and 50 µM chicoric acid displayed significantly
extended median lifespan compared to the respective controls (P<0.0001 for both; Table
4.1 and Fig 4.5B-C). Similarly, the median lifespan of daf-16 mutants was significantly
extended with the exposure of both 25 and 50 µM chicoric acid compared to the control;
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14 days for the control (daf-16 mutants) vs. 18 and 20 days with chicoric acid at 25 and
50 µM, with P=0.0012 and P=0.05, respectively (Fig 4.5D). These results indicate that
chicoric acid may act independently of the insulin/IGF-1 signaling pathway in C. elegans
(113).
In addition to AMPK and the insulin signaling pathway, several other molecular
targets are known to regulate C. elegans lifespan, such as SKN-1 and EAT-2. SKN-1/Nrf2 transcription factor has been found to mediate C. elegans lifespan extension mainly
through the oxidative stress response pathway (115, 116). From Table 4.1 and Fig 4.5E,
skn-1 mutation abolished chicoric acid-induced lifespan extension, suggesting that skn-1
is required for chicoric acid-mediated lifespan extension. Lastly, we tested eat-2 mutant,
which has defects of pharyngeal pumping that leads to prolonged lifespan via dietary
restriction pathway (117). As shown in Table 1 and Fig. 4.5F, chicoric acid treatments
shortened the median lifespan of eat-2 deficient mutant, indicating the extended lifespan
by chicoric acid might not occur through modulation of dietary intake. Since the
observations that 25 and 50 µM chicoric acid led to similar effects on the aging and
lifespan of mutants, we used 25 µM chicoric acid for the rest of the experiments.
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Table 4.1 Effect of chicoric acid on median lifespan of wild type and mutant C. elegans.

Strain
N2

aak-2 (ok524) X

daf-2 (e1370) III

age-1 (hx546) II

daf-16 (mgDf50) I

skn-1(zu135) IV

eat-2(ad1116) II

Chicoric acid
treatment (µM)
Control

Median lifespana
(days)
19

25

23***

50

22***

Control

12

25

12

50

14

Control

32

25

36***

50

38***

Control

28

25

32***

50

32*

Control

14

25

18**

50

20***

Control

16

25

18

50

18

Control

32

25

24***

50

26*

Genetic
requirementb
-

Yes

No

No

No

Yes

No

All strains were raised at 20 C, except daf-2 (e1370) III, which was raised at 15 °C.
Worms were treated with chicoric acid (25 or 50 µM) from the L4 stage (day 0).
Floxuridine (FUdR) was added with a final concentration of 120 µM. The survivals were
recorded every other day until all the worms died. a The median lifespan was referred to
the time when survival rate dropped to 50%. *, **, and *** mean significant difference
compare with their respective control at P<0.05, P<0.01 and P<0.001, respectively (n =
180–266 worms/treatment). b Significant differences were analyzed by Log-rank (MantelCox) tests. Genetic requirement was defined as “Yes” at P<0.05 or “No” at P>0.05.
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Figure 4.5. Survival of several mutant strains treated with chicoric acid. (A-F) Loss of
function mutant strains in several genes related to lifespan regulation were treated with
final concentrations of 0 (control), 25, or 50 µM chicoric acid starting from L4 stage (day
0). The survivals were recorded every other day until all the mutants died (n = 180–266
worms/treatment). Log-rank (Mantel-Cox) test was used for statistical analysis.

4.1.3.4 Chicoric acid might extend C. elegans lifespan via the regulation of AAK-2
and SKN-1.
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Since the loss of aak-2 and skn-1 abolished chicoric acid-mediated lifespan
extension, we determined the role of aak-2 and skn-1 in chicoric acid’s effect on lifespan
extension. First, we found that chicoric acid upregulated the mRNA expression of aak-2
(Fig. 4.6A). Since it is known that AAK-2 can be regulated post-translationally (97, 118,
119), we measured the role of chicoric acid in phosphorylation of AAK-2 and found that
chicoric acid significantly increased the phospho-AAK-2 level (P<0.001, Fig. 4.6B and
C). We further determined the mRNA expression of a downstream target of AAK-2, nhr49, a homolog of peroxisome proliferator-activated receptor alpha (PPARα) (120). As
shown in Fig. 4.6A, chicoric acid treatment significantly increased expression of nhr-49
compared to the control (P=0.0066).
Chicoric acid also significantly upregulated gene expression of skn-1 (Fig. 4.6A).
Similar to AAK-2, SKN-1 can be regulated post-translationally, which can be measured
by nuclear translocation of SKN-1 in C. elegans (121). Chicoric acid treatment
significantly promoted SKN-1 translocation from the cytoplasm to the nuclei (P=0.0041,
Fig 4.6D), suggesting potential post-translational regulation of SKN-1 by chicoric acid.
Next, we further tested two SKN-1 target genes, gsr-1 (glutathione reductase) and pbs-5
(proteasome beta subunit) (122-124), which were increased by chicoric acid treatment – a
1.7-fold and 2.4-fold increase over the control, with P=0.0259 and P=0.0112,
respectively (Fig. 5A).
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Figure 4.6 Chicoric acid might extend C. elegans lifespan via the regulation of AAK-2
and SKN-1. Synchronized L1 worms were treated with 0 or 25 µM chicoric acid for 48 h
(A). The mRNA expression of aak-2, nhr-49, skn-1, gsr-1, and pbs-5 were determined by
real-time PCR. ama-1 was used as an internal control. (B) Phospho-AAK-2 and tubulin
were determined by immunoblotting. (C) p-AAK-2/Tubulin, phospho-AAK-2/Tubulin.
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Values are means ± S.E. (n=3), *P<0.05, **P<0.01, and ***P<0.001. (D) Intracellular
localization of SKN-1::GFP. The nuclear translocation patterns of SKN-1::GFP were
identified as ‘low’, ‘medium’ and ‘high’. (E) Nuclear translocation of SKN-1 in ldIs7;
worms treated with chicoric acid were analyzed using the chi square test, and therefore
do not show standard error bars (control, n=94; NaN3, n = 82; chicoric acid 25 μM, n =
107). A NaN3 (2%) treated group was used as the positive control. ** and *** mean
significant difference compared with the control at P<0.01 and P<0.001, respectively.
4.1.3.5 Chicoric acid enhanced oxidative stress resistance in wild type N2 worms but
not aak-2 mutants
As aak-2 has been reported to regulate oxidative stress resistance in nematodes
(119), we then evaluated the influence of chicoric acid on oxidative stress responses of
wild type worms and aak-2 mutants. After 2, 4, and 6 days of paraquat exposure, the
survival of chicoric acid-treated wild type worms was consistently improved over that of
the control (12.2%, 12.8%, and 20.8% improvement for 25 µM chicoric acid with
P<0.001, P=0.002, and P<0.001, respectively, Fig 4.7A). As shown in Fig 4.7B, the
beneficial effect of chicoric acid against oxidative stress was abolished in aak-2 mutants,
suggesting an essential role of AAK-2 in chicoric acid-enhanced oxidative stress
resistance in C. elegans.
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Figure 4.7 Chicoric acid enhanced the stress resistance of wild type worms but not aak-2
mutants. Wild type worms and aak-2 mutants (day 1 adults) were exposed to 5 mM
paraquat with or without chicoric acid for 2, 4, and 6 days and survivals were counted.
Values are means ± S.E. (n = 3; 120-145 worms/treatment), **P<0.01 and ***P<0.001.

4.1.4

Discussion
In the current study, we found that chicoric acid at 25 and 50 µM significantly

extended the lifespan of C. elegans. These findings are consistent with a previous study
showing that chicoric acid at 25 µM or higher concentrations extended C. elegans
lifespan (7). Here, we further investigated that chicoric acid-induced lifespan extension
was accompanied by the prevention of age-associated declines of pumping rate and
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locomotor activity as well as reduced oxidative stress sensitivity without influencing
other physiological functions. The effects of chicoric acid was determined to be mediated
in part by cellular energy sensor, AAK-2, and oxidative stress responsive transcription
factor, SKN-1, but not via the insulin signaling pathway or dietary restriction.
C. elegans lifespan extension is closely associated with enhanced stress
resistance, including oxidative stress (125). Increased oxidative stress, resulting from the
excess production of free radicals, typically ROS, accelerates the aging of C. elegans
(70). Here, we found that chicoric acid reduced ROS level in vivo and increased survivals
under an oxidative stress condition, which is consistent with previous reports that
chicoric acid reduced ROS and enhanced oxidative stress resistance in RGC-5 rat retinal
ganglion cells and SH-SY5Y human neuroblastoma (67, 75). Antioxidative compounds,
including chicoric acid, may directly act as ROS scavenger and/or indirectly activate
stress-related signaling pathways, although based on the current results, it is not clear
how chicoric acid elicits its effects on ROS.
The aak-2 gene encodes an isomer of the AMPKα in C. elegans (108). A few
studies have reported that aak-2 is intimately involved in the control of C. elegans
lifespan through the regulation of dietary restriction and/or stress resistance (96, 108110). Based on the significant effect by chicoric acid on eat-2 mutants, we determined
that chicoric acid elicits its protective effects via stress resistance. In particular, Lee et al.
(119) reported that aak-2 mutations are hypersensitive to paraquat-induced oxidative
stress, suggesting an important role of aak-2 to C. elegans oxidative stress responses.
This is supported by the current observation that aak-2 deficiency completely abolished
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the chicoric acid-mediated lifespan extension and survival during the oxidative stress
conditions in C. elegans (Table 4.1 and Fig.4.5). The nhr-49 is one of the downstream
genes of aak-2 (120), and it was suggested that NHR-49 may participate in oxidative
stress responses and prevent ROS-induced toxicity in C. elegans (121). In fact, MorenoArriola et al. suggested that phospho-AAK-2 can regulate oxidative metabolism through
increased transcriptional activity of nhr-49 (126). Thus, chicoric acid may extend lifespan
in part via a mechanism dependent upon aak-2 and its target, nhr-49. However, since we
were not able to determine the effects of chicoric acid on AAK-2 due to lack of available
antibodies for AAK-2 of C. elegans, it is not conclusive that chicoric acid upregulated
AAK-2 transcriptionally and/or post-translationally with the current results only.
skn-1 is also involved in chicoric acid-induced lifespan extension in C. elegans.
SKN-1 starts regulating C. elegans lifespan as early as the postembryonic stage by
activating cellular defense responses to oxidative stress (127). This was further supported
by the fact that loss of function mutants in skn-1 are sensitive to oxidative stress and the
transgene of SKN-1::GFP rescues their embryonic developmental defect (115). It was
reported that nuclear translocation of SKN-1 results in the higher cellular oxidative stress
resistance in C. elegans (121). The current study showed that chicoric acid induced
translocation of SKN-1 from the cytoplasm to nuclei with minimum enhancement of skn1 expression. This may suggest that chicoric acid’s effect on post-translational regulation
of SKN-1 contributes significantly to the antioxidation and lifespan benefits of chicoric
acid in C. elegans. This was further confirmed by the observation of increased expression
with chicoric acid treatment of two downstream genes of SKN-1, glutathione reductase
(gsr-1) and proteasome subunit (pbs-5), which are essential for oxidative stress tolerance
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in C. elegans (122). However, it is not clear if chicoric acid regulates SKN-1 directly or
by regulating upstream regulators of SKN-1. In fact, AAK-2 was suggested to be the
upstream of SKN-1 for metformin-mediated lifespan extension in a previous publication
(96). Moreover, another study suggested that glycogen synthase kinase-3 (GSK-3) is the
upstream of SKN-1 contributing to the increased resistance of oxidative stress in C.
elegans (128). Thus, future experiments are needed to determine the target of chicoric
acid on enhanced oxidative stress resistance.
Moreover, both AAK-2 and SKN-1 have been reported to regulate mitochondrial
biogenesis against oxidative stress and contribute to longevity in C. elegans, suggesting
the possible effect of chicoric acid on mitochondrial function (98, 129). One study
reported that chicoric acid promotes mitochondrial biogenesis by increasing citrate
synthase activity and the deacetylation of peroxisome proliferator-activated receptor-γ
coactivator, which is directly activated by AMPKα (7). Thus, we cannot exclude the
possibility that chicoric acid extends lifespan via a mitochondrial biogenesis-mediated
mechanism.

Chicoric acid is metabolized to 2-caffeoyl-L-tartaric acid (cafraric acid) and
caffeic acid by rat liver microsomes (76). A recent study reported that chicoric acid has
low absorption in rats, with peak plasma concentration at 3.44±0.53 µM after 4 h of oral
administration of chicoric acid at 50 mg/kg body weight (91). Thus, the 25 µM of
chicoric acid used in the current study might be difficult to achieve in animals and
humans. Moreover, currently the comparability of chicoric plasma concentration between
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C. elegans and other in vivo models is not known; thus, it is important to determine the
biological relevance of chicoric acid in humans.
In conclusion, chicoric acid significantly extended the lifespan of C. elegans in
part through regulation of aak-2 and skn-1. Because of the high conservation of these two
genes between nematodes and mammals, these findings indicate that chicoric acid may
have potential for promoting healthy aging as well as combatting age-related diseases in
humans.

Fig. 4.8 The graphic contents. Chicoric acid significantly extended the lifespan of C.
elegans and increase the oxidative stress resistance in part through regulation of aak-2
and skn-1.
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4.2
4.2.1

Effect of chicoric acid on glucose uptake and the underlying mechanism
Introduction
Type 2 diabetes mellitus (T2DM) has been recognized as a major public health

challenge throughout the world in recent decades (8, 9). Impaired glucose uptake in
muscle tissues is the primary associated with hyperglycemia in T2DM (10). Upon insulin
signaling, protein kinase B, also known as Akt, is activated by phosphorylation that leads
to translocation of glucose transporter 4 (GLUT4) to the plasma membrane, which
subsequently promotes glucose uptake (126, 130-132). In addition to insulin signaling,
several studies indicated that AMP-activated protein kinase α (AMPKα), which is known
to regulate energy homeostasis (133, 134), also activates Akt, independent of insulin, and
results in increased glucose uptake (135, 136).
Accumulating evidence suggests that many natural bioactive components have
great potential to be used for the prevention or amelioration of T2DM (126, 137). Among
natural bioactives, chicoric acid has been recently reported to have potential anti-diabetic
effects (11, 51, 73). It is a naturally occurring dicaffeoyl ester often found in chicory
plants and basil (Fig. 1A) (138, 139). One study reported that chicoric acid promoted
glucose uptake in L6 muscle cells (11). More recently, another study revealed that
chicoric acid regulated glucose homeostasis, stimulated the AMPKα pathway, and
reversed insulin resistance in HepG2 cells (52). However, it is still not clear whether
chicoric acid enhances glucose uptake in muscle cells via an AMPKα-mediated pathway.
A better understanding of chicoric acid’s impact in promoting glucose uptake in muscle
cells would be significant given that muscle is responsible for approximately 75% of
glucose disposal in the body (140). We used C2C12 myotubes, derived from murine
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skeletal muscle cells and a C57BL/6J mice model to determine the role of chicoric acid
on glucose homeostasis and its underlying mechanisms (141, 142).

4.2.2

Materials and methods

4.2.2.1 Materials
Chicoric acid (≥ 98%) was obtained from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA, USA). C2C12 murine skeletal myoblasts were from American Type Cell
Collection (Manassas, VA, USA). Bovine serum albumin, recombinant human insulin,
and a penicillin/streptomycin mixture were purchased from Thermo Fisher (Waltham,
MA, USA). Dulbecco’s Modified Eagle’s Medium (DMEM), Kaighn’s Modification of
Ham’s F-12 (F-12K), fetal bovine serum (FBS), dimethyl sulfoxide (DMSO), 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, purity ≥ 93%), and horse
serum (HS) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Dorsomorphin
dihydrochloride (purity≥98%), also named Compound C, was purchased from MedChem
Express (Monmouth Junction, NJ, USA). The protein content was determined using
protein DC assay kits from Bio-Rad Co. (Hercules, CA, USA). Rabbit antibodies for
phospho-Akt (Ser473), Akt (total), phospho-AMPKα, AMPKα (total), phospho-acetylCoA carboxylase (ACC) (Ser79), ACC (total), mouse antibody for GLUT4, goat antirabbit IgG-horseradish peroxidase (HRP), and goat anti-mouse IgG-HRP were obtained
from Cell Signaling Technology (Danvers, MA, USA). Rabbit antibodies for β-actin and
Na+/K+-ATPase were purchased from Santa Cruz Biotechnology, Inc (Dallas, TX, USA).

4.2.2.2 C2C12 culture
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C2C12 cells were cultured in a 5% CO2 atmosphere at 37°C. Myoblasts were
cultured and differentiated into multinucleated myotubes based on previous studies (143).
After 6 days of differentiation, myotubes were treated with chicoric acid (12.5, 25, and 50
µM) for 24 h. For insulin treatment, 100 nM insulin was added into media for 30 min
before the harvest of cells. A previous study reported that 20 µM Compound C inhibited
the activity of AMPKα in primary hepatocytes (144). In the current model, 10 µM
Compound C was able to inhibit AMPKα phosphorylation in C2C12 cells. Thus, 10 µM
Compound C was used in this study. An MTT-based cell viability test was used to
determine the cytotoxicity of chicoric acid (145). Briefly, C2C12 myoblasts were seeded
in 96-well plates at a density of 1 ×106 cells/mL. Cells were treated with 12.5, 25, and 50
μM of chicoric acid for 24 h. The medium was then replaced with 5 mg/mL MTT in
DMEM (without phenol red) for 4 h at 37°C. After incubation, cells were washed thrice
with phosphate-buffered saline (PBS) and formazan crystals dissolved in DMSO were
measured with microplate reader SpectraMax i3 (Sunnyvale, CA, USA) at 570 nm.
Concentrations of chicoric acid tested (0-50 µM) were not toxic to C2C12 cells as shown
in Fig. 4.9A.

4.2.2.3 Glucose uptake assay
For glucose uptake measurement, 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4yl)amino)-2-deoxyglucose (2-NBDG), a fluorescent derivative of glucose, was used as
described previously (143). Myoblasts were seeded in the 24-well plates. After 6 days of
differentiation, myotubes were treated with various doses of chicoric acid in F-12K (5.5
mM glucose) serum free media for different time periods as shown the Figure legends.
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C2C12 myotubes were then treated with and without 100 nM insulin for 30 min in a
Krebs-Ringer buffer that was prepared as published previously (146). Insulin (30 min)
stimulation was used to activate insulin signaling in C2C12 myotubes as previously
described (147, 148). After insulin stimulation, the 2-NBDG solution was added to each
well at a final concentration of 200 µM, and the cells were incubated at 37 °C for 30 min.
Cells were then rinsed thrice with ice cold PBS and the fluorescence was immediately
measured using the SpectraMax i3 microplate reader at excitation/emission 465/540 nm.
The cell lysate was prepared by adding 40 µl 0.1 M NaOH per well. The protein content
of each well was determined by protein DC assay kits. The fluorescence was normalized
by protein content.

4.2.2.4 Cell membrane protein extraction
Integral membrane proteins and membrane-related proteins from C2C12
myotubes were prepared using a Mem-PER Plus Membrane Protein Extraction Kit from
Thermo Fisher Scientific (Waltham, MA, USA) according to the manufacturer’s
instructions. GLUT4 translocated to membrane and total GLUT4 were determined by
immunoblotting.

4.2.2.5 Transfection of shRNA-AMPKα
Lentivirus-mediated short hairpin RNA (shRNA) targeting of the mouse
AMPKα1 gene (shAMPKα) was established by Shanghai R&S Biotechnology Co. Ltd
(Shanghai, China). Detailed information is provided in supplementary data
(Supplementary Table S1 and Figure S2). The effective target sequence
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ACGAGTTGACCGGACATAAAA in the mouse AMPKα1 gene (GeneID:
NM_001013367.3) was selected, and a scrambled sequence:
GAAATGTACTGCGCGTGGAGACGTTTTGGCCACTGACTGACGTCTCCACGCA
GTACATTT that had no significant homology to any mouse gene sequences was used as
a negative control (shControl). Transfection of shRNA was performed based on the
manufacturer’s instructions. A virus counted with approximately 100 multiplicity of
infection (MOI) was used to infect one well of cells in a 6-well plate for 12 h in a serumfree medium with polybrene (8 µg/mL), and the cell culture medium was then changed to
a normal medium containing 10% FBS. After 48 h incubation, cells were treated with
chicoric acid (0 or 25 µM) for 24 h. AMPKα protein levels were measured by Western
blotting.

4.2.2.6 Western blotting
C2C12 cell lysate was prepared for immunoblotting as described previously (107,
148). Protein concentrations were determined by the protein DC assay kits. β-Actin was
used as an internal control. Horseradish peroxidase-conjugated goat anti-rabbit IgG was
used as the secondary antibody. Protein blots were pictured by the Image Station
4000MM (Carestream Health, New Haven, CT, USA) with a Clarity Western ECL
Substrate Kit (Bio-Rad Co.). Images were quantified with ImageJ software (version 1.49,
National Institutes of Health, MD, USA).

4.2.2.7 AMP/ATP assay
The measurement of AMP and ATP from C2C12 myotubes was conducted using
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a mouse AMP/ATP ELISA kit (Shanghai Fan Ke Biotechnology Co., Ltd., Shanghai,
China). Briefly, C2C12 cells were treated with chicoric acid (25 µM) for 24 h, followed
by washing with cold PBS twice at 4°C. Then cells were diluted by PBS to reach the final
concentration 1 x 107 cells/ml. The diluted cells were lysed with a lysis buffer according
to the manufacturer’s instructions. The supernatant was obtained by centrifugation for 20
min at the speed of 3000 rpm. Then the supernatant of cell lysate was taken to detect the
levels of AMP and ATP following the protocol of the ELISA kit. The absorbance of each
sample was read by the Multiskan FC microplate reader (Thermo Fisher Scientific,
Waltham, MA, USA) at 450nm after adding a stop solution for 15 min.

4.2.2.8 Glucose tolerance test (GTT)
Male C57BL/6J mice (8 week) were obtained from the Laboratory Animal
Research Center of Jiangsu University (Jiangsu, China) and maintained on a 12 h
light/dark cycle with free access to food and water for 2 weeks. Institutional guidelines
(serial No. UJS-LAER-2018042301) for animal care and use were followed, and the
animal protocol was approved by the animal ethics committee of Jiangsu University.
After adaptation, the mice were divided into two groups (6-8 mice/group). For the
treatment groups, mice received a daily oral administration of 5 mg/kg BW chicoric acid
for 5 days, based on a previous publication (59). For the control group, mice will be
administrated with saline solution orally. Mice body weight will be measured before
glucose tolerance test (GTT). On the fifth day, all mice will be fasted for 12 h following
the first measurement of blood glucose from the tail vein by a blood glucose meter (0 min,
ACCU-CHEK, Jiangsu, China). Then, all mice will be subjected to an intraperitoneal
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GTT (2 g glucose/kg BW). The blood glucose levels will be further monitored at 15, 30,
60, and 120 min. The areas under the curves (AUCs) were calculated with Sigma Plot
(version 11.0, Systat Software, Inc, San Jose, CA, USA).

4.2.2.9 Statistical analysis
SAS software (version 9.3, SAS Institute Inc., Cary, NC, USA) was used for
statistical analysis. One-way analysis of variance (ANOVA) was used for all data except
for Fig. 4.9B, Fig. 4.10A, Fig. 4.11B, Fig. 4.13, and Fig. 4.14, where two-way ANOVA
with least squares means statement was used. When there were no interactions between
chicoric acid and another factor (insulin or time), no letter was used in the figures. If
there were significant interactions between chicoric acid and another factor (Compound
C or shAMPK), letters were used in the figures to present the differences between each
group. The Tukey−Kramer method was applied for the multiple comparisons among the
groups. A difference was considered significant at P<0.05.

4.2.3

Results

4.2.3.1 Chicoric acid promoted glucose uptake
When overall glucose uptake was measured by using 2-NBDG from C2C12
myotubes, there were significant effects of insulin (P=0.0006) and chicoric acid (P<
0.0001) without any significant interaction between insulin and chicoric acid (Fig. 4.9A).
Glucose uptake in insulin-stimulated groups was 20%-25% higher than in non-insulinstimulated groups. This is consistent with previous reports that less than 30% increase of
glucose uptake after insulin stimulation with 2-NBDG (149, 150). The exposure of
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C2C12 cells to chicoric acid at the concentrations of 25 and 50 µM resulted in significant
increases in glucose uptake regardless of insulin stimulation compared to the controls (P=
0.001 and P=0.009, respectively, Fig. 4.9B). The effect of increased glucose uptake by
chicoric acid (25 µM) peaked after a 24 h treatment, and was significantly 36% greater
than the control group (P<0.0001; Fig. 4.9C); thus, a 24 h chicoric acid treatment was
used for the subsequent experiments.
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Figure 4.9 Chicoric acid promoted glucose uptake in C2C12 myotubes. (A)
Concentrations of chicoric acid tested (0-50 µM) were not toxic to C2C12 cells. (B)
Glucose uptake was measured from myotubes that were treated with chicoric acid (12.5,
25 or 50 µM) for 24 h, followed by a 30-min treatment with or without 100 nM of insulin.
(C) Myotubes were treated with 25 µM chicoric acid for 12 h, 24 h or 48 h in F-12K (5.5
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mM glucose) serum free media, respectively. Since glucose uptake was induced by
chicoric acid independent of insulin, no insulin stimulation was conducted in this test.
After washing thrice, 2-NBDG solution was added to each well at a final concentration of
200 µM, and the cells were incubated at 37 °C for 30 min. Cells were then rinsed thrice
with ice cold PBS and the fluorescence was immediately measured using the SpectraMax
i3 microplate reader at excitation/emission 465/540 nm. Numbers are mean ±S.E. (n=5).
Means with different letters are significantly different at P<0.05.

We also conducted in vivo glucose tolerance tests (GTT) to determine if chicoric
acid supplementation would have the similar results. There were significant effects in
GTT for time (P< 0.0001) and chicoric acid (P< 0.0001) without any significant
interaction between time and chicoric acid (Fig. 4.10A). Chicoric acid treatment (5 mg/kg
BW for 5 days) led to a 14.5% reduction of the overall blood glucose level compared to
the control (P< 0.0001; Fig. 2A). The areas under the curves (AUCs) in GTT further
confirms that chicoric acid treatments improved glucose tolerance in mice (P= 0.0065,
Fig. 4.10B).
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Fig. 4.10 Effects of chicoric acid on glucose tolerance test (GTT). Mice were
administrated with (0 and 5 mg/kg BW/day) chicoric acid orally for 5 days. (A) Blood
was collected from the tail vein, and glucose levels were measured at 0 min, then the
glucose solution (2 g/kg BW) was administered by intraperitoneal injection and blood
glucose level were determined at 15, 30, 60 and 120 min. (B) Area under the curve
(AUC). Values are means ±S.E. (n = 6), **P<0.01. Means with different letters are
significantly different at P< 0.05.
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4.2.3.2 Effects of chicoric acid on Akt activation and GLUT4 translocation in C2C12
myotubes
It is known that the activation of Akt (phosphorylated-Akt, p-Akt) and GLUT4
translocation to the plasma membrane directly regulate glucose uptake in muscle cells (9,
131). Thus, we examined the effects of chicoric acid on the phosphorylation of Akt and
GLUT4 translocation from C2C12 myotubes. Fig. 4.11A and 4.11B show that the ratio of
p-Akt/Akt (as an indicator of activation of Akt) was significantly increased by insulin
(P<0.0001) and chicoric acid (P=0.0003), without any interaction between insulin and
chicoric acid. These results are consistent with the results in Fig. 4.9A that chicoric acid
promoted glucose uptake in an insulin-independent manner. From these results, we
selected 25 µM chicoric acid to determine its effect on GLUT4 translocation since this
concentration had the highest activation of Akt, a 132% increase over the control in this
model (P<0.0001; Fig. 4.11A). As shown in Fig 4.11C-E, the treatment of 25 µM
chicoric acid resulted in a 28% increase in GLUT4 translocation to the cell membrane
compared to the control (P=0.0086) without altering total GLUT4 expression. These
results suggest that chicoric acid activated Akt independently of insulin and promoted
GLUT4 translocation to the plasma membrane.
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Figure 4.11 Activation of Akt and translocation of glucose transporter 4 (GLUT4) by
chicoric acid in C2C12 myotubes. (A) Myotubes were treated with the indicated
concentrations of chicoric acid for 24 h and/or 100 nM insulin for 30 min in F-12K
serum-free medium. Then phosphorylation of Akt and total Akt was determined by
immunoblotting. (B) p-Akt/Akt, phosphorylated protein kinase B/protein kinase B. (C)
Chicoric acid induced translocation of GLUT4. C2C12 myotubes were treated with 25
µM of chicoric acid for 24 h. Then the protein of plasma membrane and whole cells were
extracted to immunoblotting. (D) Mem-GLUT4/ Na+/K+-ATPase, GLUT4 on cell
membrane/internal reference on cell membrane. (E) Total GLUT4/β-actin, GLUT4 in
whole cells/internal reference in whole cells. Numbers are mean ±S.E. (n=3), **P<0.01.
Means with different letters are significantly different at P< 0.05.

4.2.3.3 Effects of chicoric acid on the AMPKα signaling pathway in C2C12
myotubes
Based on previous reports that chicoric acid promoted AMPKα activation in L6
myocytes (73), and AMPKα can activate Akt (135, 136), we determine if the effect of
chicoric acid (12.5 and 25 µM) on Akt was dependent upon AMPKα (Fig. 4.12). First,
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we have confirmed that chicoric acid (25 µM) activated AMPKα (the ratio of pAMPKα/AMPKα) with a 131% increase over the control (Fig. 4.12B). It was further
confirmed that phosphorylation of ACC/ACC, one of main downstream targets of
AMPKα, was consistently increased by chicoric acid treatment (Fig. 4.12C).

Figure 4.12 Activation of AMP-activated protein kinase α (AMPKα) pathway by
chicoric acid in C2C12 myotubes. (A) Myotubes were treated with chicoric acid (12.5
µM or 25 µM) for 24 h in DMEM. Phosphorylation of AMPKα and ACC and the total
were determined by immunoblotting. (B) p-AMPKα/AMPKα, phosphorylated AMPactivated protein kinase-α/AMP-activated protein kinase-α. (C) p-ACC/ACC,
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phosphorylated acetyl-CoA carboxylase/acetyl-CoA carboxylase. Numbers are mean ±
S.E. (n=4). Means with different letters are significantly different at P<0.05.

Next, we further proved that activation of AMPKα is involved in the effects of
chicoric acid on activation of Akt by using two approaches: an AMPKα inhibitor
(Compound C) and AMPKα knockdown cells. Compound C was regarded as a selective
AMPKα inhibitor with no influence on kinases that have similar structures with AMPKα
(144). Therefore, we used Compound C first to determine whether Akt activation by
chicoric acid is mediated by an AMPKα-dependent pathway (144). Both Compound C
and chicoric acid had significant effects on Akt phosphorylation, with a significant
interaction between Compound C and chicoric acid (P= 0.049). The phosphorylation of
AMPKα by chicoric acid was inhibited after treatment with Compound C (10 µM) as
expected (Fig 4.13A-B). Chicoric acid consistently upregulated Akt phosphorylation
without Compound C (P= 0.003), while chicoric acid induced Akt activation was
abolished by Compound C (Fig. 4.13A & C).
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Figure 4.13 Increased glucose uptake and activation of Akt by chicoric acid were
abolished by the inhibition of AMPKα. (A) Cells were treated with 10 µM compound C
for 12 h, then myotubes were treated with 25 µM chicoric acid for 24h. (B) pAMPKα/AMPKα, phosphorylated AMP-activated protein kinase-α/AMP-activated
protein kinase-α. (C) p-Akt/Akt, phosphorylated protein kinase B/protein kinase B.
Numbers are mean ±S.E. (n=3-5). Means with different letters are significantly different
at P<0.05.
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Next, we prepared AMPKα knockout cells to further confirm if chicoric acid had
significant effects on Akt phosphorylation and glucose uptake. As shown in Fig. 4.14A
and B, knocking-out AMPKα abolished the effects of chicoric acid on the activation of
Akt. Consistently, increased glucose uptake by chicoric acid was abolished in AMPKα
knock-out cells (Fig. 4.14C). These results indicate that chicoric acid increases the
phosphorylation of Akt and glucose uptake through an AMPKα-dependent pathway.
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Figure 4.14 Increased glucose uptake and activation of Akt by chicoric acid were
abolished by shAMPKα. (A) Cells were infected with lentivirus vectors expressing
shRNA targeting mouse AMPKα1. Phosphorylation of Akt and the total Akt were
determined by immunoblotting. (B) p-Akt/Akt, phosphorylated protein kinase B/ protein
kinase B. (C) Glucose levels were determined in C2C12 myotubes treated with 0 or 25
µM chicoric acid for 24 h. Numbers are mean ±S.E. (n=3-5). Means with different letters
are significantly different at P<0.05.
64

In aerobic respiration, an increase in AMP level has been reported to directly
induce AMPKα activation (151). Thus, we further determined if AMPKα activation by
chicoric acid is attributed to the enhanced AMP/ATP ratio. Figure 4.15 showed that the
AMP/ATP ratio was increased by 133% in the 25 µM chicoric acid treatment group
compared with the control (P<0.001), which suggests that chicoric acid activates AMPKα
via regulation of the AMP/ATP ratio.

Figure 4.15 Chicoric acid enhanced AMP/ATP ratio in C2C12 myotubes. After 24 h of
chicoric acid treatment, cells were lysed, and the supernatant lysate was taken to detect
the levels of AMP and ATP using a commercial kit. The absorbance of each sample was
determined by after incubation for 15 min. Values are means ±S.E. (n =3), ***P<0.001.

4.2.4

Discussion
Several phenolic secondary metabolites, such as chlorogenic acid and caffeic acid,

have been used as antihyperglycemic compounds in pharmaceutical formulations (11,
137). Chicoric acid, a new phenolic ester, has been reported to have a beneficial effect on
glucose transport in several studies (51, 52, 59, 73). Consistently, we demonstrated that
chicoric acid increased glucose uptake and activated Akt, particularly at 25 µM, and these
effects were dependent to AMPKα, but not insulin, in C2C12 myotubes. The
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hypoglycemic effects of chicoric acid were further confirmed in vivo using mice at 5 mg
chicoric acid/kg BW.
One in vivo study showed that chicoric acid (3 mg/kg BW) decreased the blood
glucose level by 53% with a 120 min treatment in diabetic mice (59). Others reported that
the extract from Cichorium intybus root, containing about 15 or 30 mg chicoric acid/kg
BW, significantly decreased blood glucose level after 4 days in male Wistar rats (152).
This is consistent with the current study which found that chicoric acid can significantly
reduce glucose levels in male mice. Zhu et al. (51) reported that chicoric acid ameliorated
glucosamine-induced insulin resistance through enhanced glucose uptake in HepG2 cells.
Our current results indicate that chicoric acid increased glucose uptake, independent of
insulin, in C2C12 myotubes (51, 149, 153). However, the current results are inconsistent
with Tousch et al. (11), who found chicoric acid to increase glucose uptake only with
insulin stimulation in L6 skeletal muscle cells . The inconsistency between the current
results and that of Tousch et al. might be due to the different statistical analysis methods
used for the latter (i.e. one-way, vs. two-way ANOVA in the current study). Alternatively,
the inconsistency may derive from: using different cell lines (mice vs. rat muscle cell
lines); different determination methods for glucose uptake; or a different length of
treatment time (2-NBDG with 24 h treatment in the current study vs. [3H] deoxyglucose
with 1 h treatment in Tousch et al.).
AMPKα is a master regulator of energy homeostasis by activating proteins in
catabolism pathways while turning off biosynthetic pathways (154). In cellular
respiration, an increase in AMP level relative to ATP activates AMPKα, which further
stimulates the acute upregulation of ATP production and the downregulation of non66

essential energy expenditure (155). Previous evidence also suggests that AMPKα is an
important regulator of glucose transport, especially in muscle tissue by phosphorylation
of insulin receptors, independent of insulin (135). Moreover, chicoric acid was previously
reported to activate AMPKα, which was suggested to be involved in the regulation of
glucose metabolism in HepG2 cells (52). In our study, a different cell line (C2C12
myotubes) was used, and we further found that chicoric acid increased the cellular
AMP/ATP ratio, which might contribute to AMPKα activation. Prior study has suggested
that increased cellular AMP level may attributed to an increase in mitochondrial
respiration without a corresponding increase in ATP synthesis by oxidative
phosphorylation, a process described as uncoupling of oxidative phosphorylation (156). It
was reported that some caffeic acid phenethyl esters (CAPEs), the derivatives of caffeic
acid, activated AMPKα through uncoupling of oxidative phosphorylation-induced
increase in AMP level (156, 157). Since chicoric acid is structurally similar to CAPEs,
we speculate that the increased AMP/ATP ratio by chicoric acid may from a mechanism
similar to that of CAPEs. However, this still needs to be determined in future study.
Along with its hypoglycemic effect, there are reports of chicoric acid having other
functional properties, such as antioxidation, anti-inflammation, and anti-fatty liver
activities (63, 84). Chicoric acid has been considered a potent antioxidant agent due to its
effect on inhibiting the accumulation of reactive oxygen species and the generation of
inflammatory cytokines, such as nitrogen oxide, interleukin 6, and tumor necrosis factorα (51, 64). Others have reported that chicoric acid promotes mitochondrial biogenesis by
enhancing the citrate synthase activity and the deacetylation of peroxisome proliferatoractivated receptor-γ coactivator, which is directly activated by AMPKα (73, 154). More
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information about such properties will help us better understand chicoric acid as a
functional food bioactive.
In conclusion, chicoric acid promoted insulin-independent glucose uptake and Akt
phosphorylation by post-translational regulation of AMPKα in C2C12 myotubes, and
improved glucose tolerance in the mice model. The current study demonstrated that
chicoric acid is a potential antidiabetic nutraceutical that may be used for the prevention
or treatment of diabetes.

Fig. 4.16 The graphic contents. Chicoric acid promoted insulin-independent glucose
uptake and Akt phosphorylation by post-translational regulation of AMPKα in C2C12
myotubes.
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